Silencing of angiotensin-converting enzyme by RNA interference prevents H9c2 cardiomyocytes from apoptosis induced by anoxia/reoxygenation through regulation of the intracellular renin-angiotensin system

International Journal of Molecular Medicine

Volumn 32, Issue 6, 2013, Pages 1380-1386

  Wan, Weiguo ^a,b   Jiang, Xuejun ^a,b   Li, Xiaoyan ^a,b   Zhang, Cui ^a,b   Yi, Xin ^a,b  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

Angiotensin converting enzyme; Anoxia reoxygenation; Apoptosis; Cardiomyocytes; RNA interference

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; CASPASE 3; DIPEPTIDYL CARBOXYPEPTIDASE; PROTEIN BAX; PROTEIN BCL 2; SHORT HAIRPIN RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOXIA; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE SILENCING; GENETIC TRANSFECTION; HEART MUSCLE CELL; IN VIVO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REOXYGENATION; REPERFUSION INJURY; RNA INTERFERENCE; UPREGULATION; WESTERN BLOTTING;

ANGIOTENSIN II; ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CELL HYPOXIA; CELL SURVIVAL; FLUORESCENCE; INTRACELLULAR SPACE; MITOCHONDRIA; MYOCYTES, CARDIAC; OXYGEN; PEPTIDYL-DIPEPTIDASE A; RATS; RENIN-ANGIOTENSIN SYSTEM; RNA INTERFERENCE; RNA, MESSENGER; TRANSFECTION;

EID: 84892180708     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1525     Document Type: Article

References (50)

1. Zijlstra F, Hoorntje JC, de Boer MJ, Reiffers S, Miedema K, Ottervanger JP, van't Hof AW and Suryapranata H: Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med 341: 1413-1419, 1999.
2. Boersma E: Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J 27: 779-788, 2006.
3. Braunwald E and Kloner RA: Myocardial reperfusion: a double-edged sword? J Clin Invest 76: 1713-1719, 1985.
4. Yellon DM and Hausenloy DJ: Myocardial reperfusion injury. N Engl J Med 357: 1121-1135, 2007.
5. Peuhkurinen K: Myocardial reperfusion-a double-edged sword? Duodecim 105: 822-830, 1989 (In Finnish).
6. Burniston JG, Saini A, Tan LB and Goldspink DF: Angiotensin II induces apoptosis in vivo in skeletal, as well as cardiac, muscle of the rat. Exp Physiol 90: 755-761, 2005.
7. Re R: Intracellular renin-angiotensin system: the tip of the intracrine physiology iceberg. Am J Physiol Heart Circ Physiol 293: H905-H906, 2007.
8. Zablocki D and Sadoshima J: Knocking out angiotensin II in the heart. Curr Hypertens Rep 13: 129-135, 2011.
9. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, et al: A novel angiotensin- converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87: E1-E9, 2000.
10. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G and Turner AJ: A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275: 33238-33243, 2000.
11. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, et al: Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 277: 14838-14843, 2002.
12. Yang XP, Liu YH, Shesely EG, Bulagannawar M, Liu F and Carretero OA: Endothelial nitric oxide gene knockout mice: cardiac phenotypes and the effect of angiotensin-converting enzyme inhibitor on myocardial ischemia/reperfusion injury. Hypertension 34: 24-30, 1999.
13. Costerousse O, Allegrini J, Clozel JP, Menard J and Alhenc-Gelas F: Angiotensin I-converting enzyme inhibition but not angiotensin II suppression alters angiotensin I-converting enzyme gene expression in vessels and epithelia. J Pharmacol Exp Ther 284: 1180-1187, 1998.
14. Houston Miller N: Cardiovascular risk reduction with renin-angiotensin aldosterone system blockade. Nurs Res Pract 2010: 101749, 2010.
15. Sim DS, Jeong MH, Kim YH, Choi S, Lim KS, Kim JH, Cho KH, Kim MC, Kim HK, Kim SS, et al: Effects of sildenafil in combination with angiotensin-converting enzyme inhibitor on limiting infarct expansion in a porcine model of acute myocardial infarction. Int J Cardiol 146: 459-460, 2011.
16. Serneri GG, Boddi M, Cecioni I, Vanni S, Coppo M, Papa ML, Bandinelli B, Bertolozzi I, Polidori G, Toscano T, et al: Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function. Circ Res 88: 961-968, 2001.
17. Both GW: Recent progress in gene-directed enzyme prodrug therapy: an emerging cancer treatment. Curr Opin Mol Ther 11: 421-432, 2009.
18. Suckau L, Fechner H, Chemaly E, Krohn S, Hadri L, Kockskämper J, Westermann D, Bisping E, Ly H, Wang X, et al: Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation 119: 1241-1252, 2009.
19. Brosnahan MM, Damiani A, van de Walle G, Erb H, Perkins GA and Osterrieder N: The effect of siRNA treatment on experimental equine herpesvirus type 1 (EHV-1) infection in horses. Virus Res 147: 176-181, 2010.
20. Rui T, Feng Q, Lei M, Peng T, Zhang J, Xu M, Abel ED, Xenocostas A and Kvietys PR: Erythropoietin prevents the acute myocardial inflammatory response induced by ischemia/reperfusion via induction of AP-1. Cardiovasc Res 65: 719-727, 2005.
21. Chen HP, He M, Huang QR, Liu D and Huang M: Sasanquasaponin protects rat cardiomyocytes against oxidative stress induced by anoxia-reoxygenation injury. Eur J Pharmacol 575: 21-27, 2007.
22. Koyama T, Temma K and Akera T: Reperfusion-induced contracture develops with a decreasing [Ca2+]i in single heart cells. Am J Physiol 261: H1115-H1122, 1991.
23. Palojoki E, Saraste A, Eriksson A, Pulkki K, Kallajoki M, Voipio-Pulkki LM and Tikkanen I: Cardiomyocyte apoptosis and ventricular remodeling after myocardial infarction in rats. Am J Physiol Heart Circ Physiol 280: H2726-H2731, 2001.
24. Fliss H and Gattinger D: Apoptosis in ischemic and reperfused rat myocardium. Circ Res 79: 949-956, 1996.
25. Danial NN and Korsmeyer SJ: Cell death: critical control points. Cell 116: 205-219, 2004.
26. Arumugam TV, Chan SL, Jo DG, Yilmaz G, Tang SC, Cheng A, Gleichmann M, Okun E, Dixit VD, Chigurupati S, et al: Gamma secretase-mediated Notch signaling worsens brain damage and functional outcome in ischemic stroke. Nat Med 12: 621-623, 2006.
27. Adams JM and Cory S: The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322-1326, 1998.
28. Martinou JC and Youle RJ: Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev Cell 21: 92-101, 2011.
29. Kharbanda S, Pandey P, Schofield L, Israels S, Roncinske R, Yoshida K, Bharti A, Yuan ZM, Saxena S, Weichselbaum R, et al: Role for Bcl-xL as an inhibitor of cytosolic cytochrome C accumulation in DNA damage-induced apoptosis. Proc Natl Acad Sci USA 94: 6939-6942, 1997.
30. Kluck RM, Bossy-Wetzel E, Green DR and Newmeyer DD: The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275: 1132-1136, 1997.
31. Gross A, McDonnell JM and Korsmeyer SJ: BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13: 1899-1911, 1999.
32. Youle RJ and Strasser A: The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59, 2008.
33. Simonis G, Wiedemann S, Schwarz K, Christ T, Sedding DG, Yu X, Marquetant R, Braun-Dullaeus RC, Ravens U and Strasser RH: Chelerythrine treatment influences the balance of pro- and anti-apoptotic signaling pathways in the remote myocardium after infarction. Mol Cell Biochem 310: 119-128, 2008.
34. Brocheriou V, Hagège AA, Oubenaïssa A, Lambert M, Mallet VO, Duriez M, Wassef M, Kahn A, Menasché P and Gilgenkrantz H: Cardiac functional improvement by a human Bcl-2 transgene in a mouse model of ischemia/reperfusion injury. J Gene Med 2: 326-333, 2000.
35. Hochhauser E, Kivity S, Offen D, Maulik N, Otani H, Barhum Y, Pannet H, Shneyvays V, Shainberg A, Goldshtaub V, et al: Bax ablation protects against myocardial ischemia-reperfusion injury in transgenic mice. Am J Physiol Heart Circ Physiol 284: H2351-H2359, 2003.
36. Ohtsuka T, Ryu H, Minamishima YA, Macip S, Sagara J, Nakayama KI, Aaronson SA and Lee SW: ASC is a Bax adaptor and regulates the p53-Bax mitochondrial apoptosis pathway. Nat Cell Biol 6: 121-128, 2004.
37. Fridman JS and Lowe SW: Control of apoptosis by p53. Oncogene 22: 9030-9040, 2003.
38. Kumar R, Singh VP and Baker KM: The intracellular renin-angiotensin system in the heart. Curr Hypertens Rep 11: 104-110, 2009.
39. Kumar R and Boim MA: Diversity of pathways for intracellular angiotensin II synthesis. Curr Opin Nephrol Hypertens 18: 33-39, 2009.
40. Dell'Italia LJ and Husain A: Dissecting the role of chymase in angiotensin II formation and heart and blood vessel diseases. Curr Opin Cardiol 17: 374-379, 2002.
41. Singh VP, Le B, Bhat VB, Baker KM and Kumar R: High-glucose-induced regulation of intracellular ANG II synthesis and nuclear redistribution in cardiac myocytes. Am J Physiol Heart Circ Physiol 293: H939-H948, 2007.
42. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB and Diz DI: Counterregulatory actions of angiotensin-(1-7). Hypertension 30: 535-541, 1997.
43. Iyer SN, Chappell MC, Averill DB, Diz DI and Ferrario CM: Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension 31: 699-705, 1998.
44. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira-dos-Santos AJ, da Costa J, Zhang L, Pei Y, et al: Angiotensin- converting enzyme 2 is an essential regulator of heart function. Nature 417: 822-828, 2002.
45. Thomas MC, Pickering RJ, Tsorotes D, Koitka A, Sheehy K, Bernardi S, Toffoli B, Nguyen-Huu TP, Head GA, Fu Y, et al: Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. Circ Res 107: 888-897, 2010.
46. Tikellis C, Bialkowski K, Pete J, Sheehy K, Su Q, Johnston C, Cooper ME and Thomas MC: ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. Diabetes 57: 1018-1025, 2008.
47. Burrell LM, Risvanis J, Kubota E, Dean RG, MacDonald PS, Lu S, Tikellis C, Grant SL, Lew RA, Smith AI, et al: Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J 26: 369-375; Discussion 322-364, 2005.
48. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI and Gallagher PE: Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111: 2605-2610, 2005.
49. Harada E, Yoshimura M, Yasue H, Nakagawa O, Nakagawa M, Harada M, Mizuno Y, Nakayama M, Shimasaki Y, Ito T, et al: Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 104: 137-139, 2001.
50. Yamamuro M, Yoshimura M, Nakayama M, Abe K, Sumida H, Sugiyama S, Saito Y, Nakao K, Yasue H and Ogawa H: Aldosterone, but not angiotensin II, reduces angiotensin converting enzyme 2 gene expression levels in cultured neonatal rat cardiomyocytes. Circ J 72: 1346-1350, 2008.